Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Dr. Rian A. Maercks Announces Appointment to Elite ASCENT National Advisory Panel in Plastic Surgery, Comprised of Top 25 Leaders in Innovative Plastic Surgery in the U.S.
PR Newswire - Thu Apr 17, 7:45AM CDT
In recognition of expertise and interest in delivering the most innovative aesthetically superior treatment options, Dr. Rian A. Maercks has been appointed to the elite Allergan ASCENT advisory board of the top 25 leaders in plastic surgery in the U.S.
TauTona Group Sells Aline HA(R) to Allergan
Marketwire - Thu Apr 17, 7:30AM CDT
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.
Stocks On Track For Third Gain; Allergan Rises
at Investor's Business Daily - Wed Apr 16, 1:54PM CDT
Stocks continued to hold near their session highs Wednesday afternoon and had little reaction to the Fed's beige book. The Dow Jones industrial average and the Nasdaq rose 0.8% each, while the S&P 500 climbed 0.7%. All three were on pace for a third...
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at The Street - Wed Apr 16, 8:46AM CDT
Trade-Ideas LLC identified Allergan (AGN) as a momo momentum candidate
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.
Top-of-Mind Companies in Facial Injectable and Laser/Energy Device Markets Are Similar in Europe and Asia
PR Newswire - Tue Apr 15, 9:00AM CDT
Decision Resources Group, in collaboration with IMCAS (International Master Course on Aging Skin), finds that the top-of-mind companies in each of the botulinum toxin (BTX), dermal filler and laser/energy device markets are similar in Europe and in Asia. Not surprisingly, Allergan's BOTOX Cosmetic continues to be the top-of-mind BTX brand in both Asia and Europe, with Allergan's JUVEDERM and Galderma's Restylane both having high recognition among dermal filler brands. Lumenis came out on top for laser/energy devices in both regions.
3 Big-Volume Stocks in Breakout Territory
at The Street - Tue Apr 15, 7:23AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Global Retinal Vein Occlusion Therapeutics Pipeline Review 2014 - Analysis of 5 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jr9qs5/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Retinal Vein Occlusion - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV Drug Profiles - fluocinolone acetonide - beclomethasone dipropionate - ranibizumab - ocriplasmin - NCX-434 - NCX-422 For more information visit http://www.researchandmarkets.com/research/jr...tinal_vein
After Yesterday's Rally of 2.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 14, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $120.72 to a high of $124.46. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $121.96 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Next Resistance Level for Allergan (AGN) is $125.58
Comtex SmarTrend(R) - Mon Apr 14, 12:30PM CDT
Shares of Allergan (AMEX:AGN) opened today above their pivot of $119.62 and have already reached the first level of resistance at $123.23. Analysts will be watching for a cross of the next upside pivot targets of $125.58 and $131.54.
Regulatory Approvals, Earnings and Conference Call Schedules, and Stock Price Updates - Analyst Notes on Teva, Allergan, Boston Scientific, Covidien and Thermo Fisher
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Boston Scientific Corporation (NYSE: BSX), Covidien Plc (NYSE: COV) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1089-100free.
Active Equities under the Scanner -- Research on Allergan, Visa, Starbucks, and Home Depot
PR Newswire - Mon Apr 14, 7:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors ended the session in negative. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Allergan Inc. (NYSE: AGN), Visa Inc. (NYSE: V), Starbucks Corp. (NASDAQ: SBUX) and The Home Depot Inc. (NYSE: HD). Free technical research on AGN, V, SBUX and HD can be downloaded upon signing up at:
Why Rambus, Allergan, and JAKKS Pacific Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 7:05PM CDT
Friday didn't turn out to be quite as bad a day for the stock market as Thursday was, with major-market benchmarks ending the day down around 1% to 1.5% instead of the up to 3% losses that we saw yesterday. Nevertheless, continued weakness in some...
NYSE stocks posting largest percentage increases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
Abbott Labs Progresses with Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:40PM CDT
Abbott Laboratories (ABT) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS).
3 Health Care Stocks Moving The Sector Upward
at The Street - Fri Apr 11, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.